Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Haematol ; 87(6): 531-8, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21848700

ABSTRACT

OBJECTIVES: Granulocyte colony-stimulating factor-mobilized peripheral blood hematopoietic stem cell transplantation (HSCT) provides a valuable and increasingly used alternative to bone marrow transplantation (BMT). This retrospective study aimed at determining whether the stem cell source is predictive for outcome, relapse incidence, non-relapse mortality, and severity and incidence of both, acute and chronic graft-versus-host disease (GVHD) in patients undergoing allogeneic HSCT. PATIENTS AND METHODS: Between 1983 and 2007, 329 adult patients (median age 40, range 18-76) received a first allogeneic HSCT from either sibling (n = 203) or volunteer unrelated donors (n = 126) at our institution. The source of stem cells was bone marrow in 177 (54%) and peripheral blood in the remaining 152 (46%) patients. RESULTS: Overall survival was 37% (31-43%, 95% confidence interval, CI), the relapse incidence was 30% (25-36%, 95% CI), and the non-relapse mortality was 43% (38-49%, 95% CI) for the entire cohort with no significant differences between peripheral blood stem cell or BMT. In patients receiving myeloablative conditioning, peripheral blood stem cell transplantation (PBSCT) was associated with a significantly lower non-relapse mortality (32% vs. 46%, P = 0.05), which, however, was restricted to standard-risk disease (23% vs. 42%, P = 0.02). The overall cumulative incidences of acute GVHD II-IV were 51% and 54% following bone marrow and PBSCT, respectively. Severe acute GVHD III-IV was significantly more frequent after BMT (24% vs. 14%, P = 0.04), whereas chronic GVHD was significantly more frequent following PBSCT (48% vs. 24%, P = 0.0001). By multivariate analysis, PBSCT was only predictive for chronic GVHD (RR 2.29, P = 0.02). CONCLUSION: Although we failed to demonstrate any advantage of PBSCT over conventional BMT with regard to overall survival, relapse incidence and non-relapse mortality PBSCT were associated with a significantly higher incidence of chronic graft-versus-host disease. Therefore, and by virtue of observations, that some patient groups might benefit from either stem cell source, there is still need for prospective randomized trials with special emphasize on quality of life in long-term survivors.


Subject(s)
Bone Marrow Transplantation , Hematopoietic Stem Cell Transplantation , Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Retrospective Studies , Transplantation, Homologous
2.
Ann Hematol ; 84(7): 462-73, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15726362

ABSTRACT

Between 1990 and 2001, 68 patients with advanced Hodgkin's disease (HD) and 86 patients classified as low-/intermediate-grade B non-Hodgkin's lymphoma (NHL) were reported to the Austrian Stem Cell Transplantation Registry (ASCTR). Following autologous stem cell transplantation (SCT) for HD, overall survival was 56% [95% confidence interval (CI): 40-72%] with a disease-/progression-free survival of 49%, reaching a plateau at 5 years. Using multivariate Cox regression analysis BEAM conditioning (carmustine, cytarabine, etoposide and melphalan) was predictive for favourable outcome, better disease-/progression-free survival and a significantly lower risk for relapse. The cumulative incidence of relapse was 30%, even for patients in complete remission at time of SCT. The cumulative risk for developing a secondary malignancy increased continuously over time, achieving 20% at 7 years and 46% at 10 years with previous radiotherapy as the only risk factor in the multivariate analysis. Overall survival for NHL patients was 45% (95% CI: 26-64%) with a disease-/progression-free survival of 26% at 7 years. In the multivariate Cox regression analysis stage of disease at time of SCT was the most powerful parameter for overall survival, disease-/progression-free survival and relapse. Mantle cell lymphoma, greater than or equal to three lines of previous therapy, and a conditioning regimen other than BEAM were also predictive for death. The main reason for treatment failure was relapse (cumulative incidence 54-75%). Because of the high risk of relapse/progression in both disease categories and the additional high rate of second malignancies in HD patients, allogeneic stem cells should be considered a valuable alternative for selected patients. The efficacy of allotransplantation following reduced-intensity conditioning should be tested in randomised trials.


Subject(s)
Hematopoietic Stem Cell Transplantation , Hodgkin Disease/mortality , Hodgkin Disease/therapy , Transplantation, Autologous , Adolescent , Adult , Austria , Child , Disease-Free Survival , Female , Humans , Longitudinal Studies , Male , Middle Aged , Recurrence , Registries , Remission Induction , Retrospective Studies , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...